EPZM - Epizyme

...

Available for logged in users only.

The multiple price alert feature will smartly add or remove $1 if your alert was hit.
It's only available if you are logged in, a V.I.P. member or if you are using the AI chrome extension.

Contact us via Twitter if you are interested in trying it out.

• Epizyme GAAP EPS of -$0.21, revenue of $27.5M
• Ipsen extends tender offer date in Epizyme deal to get US antitrust clearance, required shares
• Hutchmed begins dosing in mid-stage study of tazemetostat in blood cancer subtype
• Epizyme stock soars 60% as Ipsen set to acquire the cancer drugmaker
• Hutchmed, Epizyme cancer drug Tazverik gets China's Hainan province health regulator nod
• Epizyme GAAP EPS of -$0.38 misses by $0.03, revenue of $8.69M misses by $1.33M
• Epizyme Q1 2022 Earnings Preview
• Epizyme chief medical officer Shefali Agarwal resigns
• Epizyme GAAP EPS of -$0.49 misses by $0.08, revenue of $11.6M misses by $8.82M
• Epizyme Q4 2021 Earnings Preview
• Epizyme equity offering pummels stock as shares down 40%
• Epizyme raises $85M capital via stock offering
• Epizyme announces proposed public offering of shares
• Epizyme multiple myeloma candidate granted FDA Orphan Drug Designation
• Epizyme jumps after product revenue shows strong sequential growth: Q4 Prelim
• Epizyme EPS misses by $0.11, misses on revenue
• Epizyme Q3 2021 Earnings Preview
• FDA grants Fast Track status to Epizyme's lymphoma treatment EZM0414
• Epizyme CEO Robert Bazemore steps down
• Epizyme EPS misses by $0.02, beats on revenue